Description
Indication & Scope
Kisunla® Donanemab Injection treats mild cognitive impairment and mild dementia caused by Alzheimer’s disease.
- Mechanism：Monoclonal antibody targeting amyloid-beta plaques, binds and clears accumulated amyloid-beta protein in the brain to slow neurodegeneration.
- Drug class：Anti-amyloid beta monoclonal antibody, disease-modifying therapy for Alzheimer’s disease.
- Clinical use：Disease-modifying treatment to slow cognitive decline in early-stage Alzheimer’s disease patients.
| Generic Name | Donanemab Injection |
| Brand Name | Kisunla |
| Ingredient | Donanemab Injection |
| Dosage Form | Injection |
| Package | 20ml: 350mg*1 vial/box |
| Conditions Treated | Mild cognitive impairment and mild dementia due to Alzheimer’s disease |
| Taboos | Severe hypersensitivity to donanemab or formulation components, patients with active severe intracranial inflammation, history of amyloid-related imaging abnormalities (ARIA), pregnant and breastfeeding women |
| Place of origin | Z.A.-Centre de production, 2 rue du Colonel Lilly, Fegersheim 67640, FRANCE |
| Priscription Type | Prescription-only |
| Storage Conditions | Refrigerate at 2°C~8°C, do not freeze, avoid intense shaking and sunlight |
| Manufacturer | Eli Lilly and Company |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | SJ20240047 |
| Approval Date | Dce 17, 2024 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Fixed maintenance dose administered at scheduled intervals.
Time: Regular repeated subcutaneous injections for long-term disease modification.
Instructions for use: Subcutaneous injection into abdomen, thigh or upper outer arm.
Interaction: Immunosuppressants increase infection risk; avoid concurrent use without neurological supervision.
Side effects: Amyloid-related imaging abnormalities (ARIA), headache, injection site reactions, fatigue, falls.
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What disease does Donanemab Injection treat?
It treats mild cognitive impairment and mild dementia caused by Alzheimer’s disease.
What is the core therapeutic mechanism of Donanemab Injection?
It is an anti-amyloid-beta monoclonal antibody that clears accumulated brain amyloid-beta plaques to slow neurodegeneration.
What is the administration route of Donanemab Injection?
It is delivered via subcutaneous injection in the abdomen, thigh or upper outer arm.
Who cannot receive Donanemab Injection treatment?
Patients with severe hypersensitivity, active intracranial inflammation, ARIA history, and pregnant women are contraindicated.
Kisunla® | Donanemab Injection | Alzheimer’s disease | DengYueRX
INN: Donanemab Injection
Indications: Alzheimer’s disease
Dosage Form: Injection
Strength: 20ml: 350mg/vial
